Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZEMPLAR

« Back to Dashboard
Zemplar is a drug marketed by Abbvie and is included in two NDAs. It is available from three suppliers. There are three patents protecting this drug and three Paragraph IV challenges.

The generic ingredient in ZEMPLAR is paricalcitol. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the paricalcitol profile page.

Summary for Tradename: ZEMPLAR

Suppliers: see list3

Pharmacology for Tradename: ZEMPLAR

Drug ClassVitamin D3 Analog

Clinical Trials for: ZEMPLAR

Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis
Status: Completed Condition: Secondary Hyperparathyroidism; Dialysis

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
Status: Completed Condition: Diabetic Nephropathy; Chronic Kidney Disease

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Status: Completed Condition: Chronic Kidney Disease; Secondary Hyperparathyroidism; Hemodialysis

Oral Paricalcitol in Kidney Transplant Recipients
Status: Completed Condition: Transplant; Failure, Kidney; Renal Disease, End Stage; Hyperparathyroidism, Secondary

Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation
Status: Completed Condition: Chronic Kidney Disease; Endothelial Dysfunction; Inflammation; Hypertension

The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
Status: Completed Condition: Chronic Kidney Disease

Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease
Status: Active, not recruiting Condition: Type 2 Diabetes; Chronic Kidney Disease

Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis
Status: Completed Condition: Parathyroid Hormone

Paricalcitol Effect on Anemia in CKD
Status: Completed Condition: Anemia; Chronic Kidney Disease

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
Status: Terminated Condition: Chronic Kidney Disease (CKD) Stage 5; Hypertrophy, Left Ventricular

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
SOLUTION;INTRAVENOUS020819-001Apr 17, 1998RXYes5,597,815*PED<disabled>Y<disabled>
CAPSULE;ORAL021606-001May 26, 2005RXNo5,597,815*PED<disabled>Y<disabled>
SOLUTION;INTRAVENOUS020819-002Feb 1, 2000RXYes6,136,799*PED<disabled>Y<disabled>
SOLUTION;INTRAVENOUS020819-003Feb 1, 2000RXYes6,361,758*PED<disabled>Y<disabled>
SOLUTION;INTRAVENOUS020819-001Apr 17, 1998RXYes6,136,799*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ZEMPLAR

Drugname Dosage Strength RLD Submissiondate
paricalcitolInjection0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vialsZemplar11/28/2008
paricalcitolCapsules1 mcg and 2 mcgZemplar10/14/2008
paricalcitolCapsules4 mcgZemplar8/25/2008
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn